GP-2

targets

all catalysts(0)

nothing on the calendar yet

News(8)

• ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
  When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
  fiercebiotech · 6d ago
• Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
  Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.
  fiercebiotech · 10d ago
• Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
  Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…
  fiercebiotech · 1mo ago
• TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion
  TME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings to its hope of generating $1 billion in peak sales from the asset.
  fiercebiotech · 1mo ago
• Vaderis hauls in $152M to test an AKT-targeting drug
  The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
  biopharma_dive · 1mo ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 2mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 4mo ago
• Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
  Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.
  onclive · 5mo ago